A Clinical Study GK01 Cell Injection in Subjects With Advanced Solid Tumors.

Sponsor
Beijing Geekgene Technology Co., LTD
Study ID
NCT07412665
Phase
EARLY_PHASE1
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Advanced Solid Tumors

Eligibility Criteria

Sex
ALL
Age
18 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

  • GK01 injection — DRUG
    Autologous tumor-reactive T cells injection

Study Details

This study is an open-label, single-arm clinical trial to evaluate the safety, pharmacokinetics, and preliminary efficacy of GK01 in patients with advanced solid tumors.

Key Dates

First listed
Feb 17, 2026
Start date
Jun 30, 2026
Status verified
Jun 2026
Primary completion
Mar 31, 2027
Completion
Mar 31, 2028

Study Design

Enrollment
10 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: GK01 injection
    Autologous tumor-reactive T cells injection

Primary Outcome Measure

Safety and Tolerability [ Time Frame: 2 years ]

Central Contacts

Related Studies